JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Home・Elenco Azioni・Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp

Chiusa

12.13 1.08

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

11.9

Massimo

12.65

Metriche Chiave
By Trading Economics
Entrata	3.9M -30M
Vendite	5M 52M
Margine di Profitto	-56.881
Dipendenti	619
EBITDA	-3.3M -30M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+13.17% upside

Dividendi
By Dow Jones
Utili prossimi	6 nov 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	503M 1.7B
Apertura precedente	11.05
Chiusura precedente	12.13

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bullish Evidence

8.81 / 10.18 Supporto e resistenza

Adaptive Biotechnologies Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 ago 2025, 17:49 UTC

I principali Market Mover

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 ago 2025, 17:18 UTC

I principali Market Mover

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 ago 2025, 16:25 UTC

Utili

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 ago 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

11 ago 2025, 23:42 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

11 ago 2025, 23:42 UTC

Discorsi di Mercato

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 ago 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 ago 2025, 23:32 UTC

Discorsi di Mercato

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 ago 2025, 23:02 UTC

Discorsi di Mercato

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 ago 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

11 ago 2025, 20:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 ago 2025, 20:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 ago 2025, 20:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement 2Q Rev $25.8M >EXOD

11 ago 2025, 20:14 UTC

Discorsi di Mercato

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 ago 2025, 19:12 UTC

Discorsi di Mercato

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 ago 2025, 18:56 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 ago 2025, 18:31 UTC

Discorsi di Mercato

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 ago 2025, 17:43 UTC

Discorsi di Mercato

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 ago 2025, 17:28 UTC

Discorsi di Mercato

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 ago 2025, 17:16 UTC

Discorsi di Mercato

Commodity Longs Fall to 11-Month Low -- Market Talk

11 ago 2025, 16:42 UTC

Acquisizioni, Fusioni, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 ago 2025, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 ago 2025, 16:26 UTC

Acquisizioni, Fusioni, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 ago 2025, 16:25 UTC

Acquisizioni, Fusioni, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 ago 2025, 16:25 UTC

Acquisizioni, Fusioni, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Confronto tra pari

Modifica del prezzo

Adaptive Biotechnologies Corp Previsione

Obiettivo di Prezzo

By TipRanks

13.17% in crescita

Previsioni per 12 mesi

Media 13.75 USD 13.17%

Alto 15 USD

Basso 11 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Adaptive Biotechnologies Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 8 che hanno fornito valutazioni azionarie a Adaptive Biotechnologies Corp - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

8.81 / 10.18Supporto e resistenza

Recent bullish events outweigh bearish events.

All events are bullish.

There is one bullish event.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.